Horizon scanning for novel therapeutics for the treatment of prostate cancer.

about

Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.The changing therapeutic landscape of castration-resistant prostate cancer.Anti-angiogenic therapies in prostate cancer

P2860

Q37709535-F7A01D5C-B535-4A17-87A0-A7A489E87117 Q37913983-855C634F-E8E5-4393-8EBD-14C10C9D9E97 Q57132472-27C56FB6-CCE8-4CDB-91F4-C19486685F53

P2860

Horizon scanning for novel therapeutics for the treatment of prostate cancer.

Item

http://www.wikidata.org/entity/Q37792060

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 24 September 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Horizon scanning for novel therapeutics for the treatment of prostate cancer.

@en

type

Item

label

Horizon scanning for novel therapeutics for the treatment of prostate cancer.

@en

prefLabel

Horizon scanning for novel therapeutics for the treatment of prostate cancer.

@en

P1476

Horizon scanning for novel therapeutics for the treatment of prostate cancer

@en

P2093

Andrea Zivi

http://www.w3.org/2001/XMLSchema#string

Diletta Bianchini

http://www.w3.org/2001/XMLSchema#string

Johann S de Bono

http://www.w3.org/2001/XMLSchema#string

P2860

Cbl associates with Pyk2 and Src to regulate Src kinase activity, alpha(v)beta(3) integrin-mediated signaling, cell adhesion, and osteoclast motility

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

Clusterin inhibits apoptosis by interacting with activated Bax

The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate

Thalidomide is an inhibitor of angiogenesis

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

Mutation and cancer: statistical study of retinoblastoma

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis

Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase

P304

1487-1502

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.2010.514261

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Shahneen K Sandhu

P577

2010-09-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20868208

http://www.w3.org/2001/XMLSchema#string

Horizon scanning for novel therapeutics for the treatment of prostate cancer.

about

P2860

P2860

Horizon scanning for novel therapeutics for the treatment of prostate cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698